For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Helping travellers decide when to receive Japanese encephalitis vaccine
+Practice
Travel Medicine
Helping travellers decide when to receive Japanese encephalitis vaccine
Saturday 15 February 2025, 12:20 AM

Countries in Asia and the western Pacific in which Japanese encephalitis virus has been identified [Image: CDC]
Japanese encephalitis is a rare disease in travellers, but for those who do become symptomatic, it carries significant mortality and morbidity risk. This article discusses a new online tool to support decisions around vaccination
This Practice article has been endorsed by the RNZCGP and has been approved for up to 0.5 credits for continuing professional development purposes (2 , Educate small, BACK panel - grey
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
Lau CL, Mills DJ, Mayfield H, et al. A decision support tool for risk-benefit analysis of Japanese encephalitis vaccine in travellers. J Travel Med 2023;30(7):taad113.